2026年11月7日-13日，全球医药市场共签署了28项资产授权和合作协议。中国市场共达成9项交易，包括6项出海交易和3项国内交易。
中国市场，本周最大的交易是荣昌生物与Vor Biopharma就资产RC298达成海外授权交易，首付款5600万美元，总金额可达3.56亿美元。
中国以外市场，本周共签署了19项资产授权和合作协议。最大的交易是CorMedix Therapeutics收购Heron Therapeutics的实质性全部资产，首付款包括1.45亿美元和约定数量的公司普通股，加上高达5500万美元的或有收益付款和特许权使用费。
From November 7 to 13, a total of 28 biopharmaceutical licensing and collaboration transactions were announced globally. Of these, 9 were China-related, defined as transactions involving at least one China-based company. These comprised six out-licensing deals and three domestic partnerships.
In China, the largest transaction involved RemeGen and Vor Biopharma for the asset RC298, with an upfront payment of $56million and a total deal value of $356 million.
Outside China, 19 deals were announced. The largest transaction involved CorMedix Therapeutics’ acquisition of substantially all of Heron Therapeutics’ assets for upfront consideration of $145 million in cash, CorMedix common stock, plus up to $55 million in contingent earn-out payments and royalties on net sales of certain Heron products.
3. M&A Deals
4. Top Deals of 2026
